Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539344 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
A Phase 1 study, sponsored by Angiochem.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00539344 is a Phase 1 study that has completed, run by Angiochem. The registered enrollment target is 63 participants.
The verdict
NCT00539344, a Phase 1 study, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Interventions
- DRUG ANG1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539344
The ClinicalTrials.gov registry entry for NCT00539344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiochem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ANG1005 is the first listed.
NCT00539344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539344 about?
NCT00539344 is a clinical study titled "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma". This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate ...
What is the current status of trial NCT00539344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2007-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00539344?
The interventions under investigation include: ANG1005 (DRUG).
Who is sponsoring clinical trial NCT00539344?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.